AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03173768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ID specialist approval
Description: Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
Study NCT02189681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional landmark guided midline spinal anaesthesia
Description: Spinal anaesthesia was administered based on conventional landmark based midline approach.
Study NCT04038437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 will be administered on Days 1 and 3 of each cycle
Study NCT04038437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be adminstered on Days 2 to 21 of each cycle
Study NCT04407273 — intervention group
Intervention type: DRUG
Intervention: observational
Description: observational study
Study NCT04615351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Medication
Study NCT00228917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax-ACWY
Description: Meningococcal Serogroups A, C, W-135 and Y Vaccine
Study NCT02189681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-procedure ultrasound guided L5S1 paramedian spinal
Description: In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
Study NCT02189681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anaesthesia
Description: Spinal anaesthesia is administered with appropriate spinal needle
Study NCT02189681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal anaesthesia
Description: Spinal anaesthesia is administered with appropriate spinal needle
Study NCT03134690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed start
Description: In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
Study NCT03134690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional
Description: In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
Study NCT03504748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep rTMS
Study NCT03504748 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo deep rTMS
Study NCT05277428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GTB1
Description: 2 capsule/day
Study NCT05277428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsule/day
Study NCT01457846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
Study NCT01457846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Infusion administered once a week, 3 weeks on and 1 week off
Study NCT02526225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo diterpene lactone meglumine injection
Description: 5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
Study NCT02526225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo diterpene lactone meglumine injection simulation
Description: 5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
Study NCT04365192 — intervention group
Intervention type: DEVICE
Intervention: I-gel
Description: The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary.
Study NCT04365192 — intervention group
Intervention type: DEVICE
Intervention: Self-pressurized air-Q
Description: The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
Study NCT03093701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399 (ProDex)
Description: 2-vial system: TLC399-DSP and TLC399-Lipid
Study NCT04196010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT04196010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT04196010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given subcutaneously
Study NCT04196010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV
Study NCT00014560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bispecific antibody 4G7xH22
Study NCT00014560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00968929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Streptokinase
Description: Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
Study NCT00968929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urokinase
Description: Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
Study NCT02698176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered as an oral capsule in a fasted state
Study NCT02183220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Study NCT02183220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Study NCT02183220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol placebo
Study NCT02183220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metamizol placebo
Study NCT01207310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation counseling
Description: two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
Study NCT05082415 — intervention group
Intervention type: DRUG
Intervention: Brolucizumab
Description: Participants received brolucizumab injection during the index period
Study NCT04193774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Conjunctival swab
Description: Swab of the conjunctival fornices of both eyes
Study NCT04193774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conjunctival swab
Description: Swab of the conjunctival fornices of both eyes
Study NCT04193774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybuprocaine Hydrochloride 0.4% Eye Drops
Description: One drop of topical anesthesia in one eye
Study NCT04193774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: artificial tears
Description: One drop of artificial tears in the other eye
Study NCT02968147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation
Description: General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
Study NCT02968147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional ventilation
Description: General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
Study NCT02924909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin paclitaxel
Description: induction carboplatin paclitaxel for 2 cycles
Study NCT00254891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676 + Paclitaxel + Carboplatin
Description: * PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles.
Study NCT00254891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Carboplatin
Description: * Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles.
Study NCT01879969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: classic procedure of planning
Description: analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
Study NCT01879969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer assisted orthognathic planning and surgery of asymmetric patients
Study NCT03083145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Beverage
Description: Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
Study NCT03083145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pea Protein Beverage
Description: Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
Study NCT02183220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA placebo
Study NCT02183220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA placebo
Study NCT02102776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
Study NCT02102776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
Study NCT02102776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAG
Description: A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
Study NCT03083145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Snack Tray Choices
Description: Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
Study NCT04108806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: Ballon dialtation of the diseased artery
Study NCT02023047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 12 mg coated suppositories
Study NCT02516228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GTEN 100
Description: Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days.
Study NCT03916484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AllyQuest HIV Medication Adherence app-delivered intervention
Description: AQ provides daily ART reminders and calendar; weekly tailored message; monthly appointment and refill reminders; social support via daily chat wall; daily challenge featuring skills-building and articles; education center; narrative collections; in app account rewards daily use by adding or subtracting small financial reward dependent on daily app use; personalized profile and avatar. Participants have 24-hour access to all features of the AQ app.
Study NCT03916484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AllyQuest HIV Medication Adherence app-delivered intervention + NSC
Description: In AQ+, participants receive all of AQ and have the added ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve ART adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. AQ+ includes unprompted check-in messages from the NSC counselor and scheduled in-app NSC sessions approximately every other week.
Study NCT00154882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Phyxol) , Cisplatin
Study NCT02736981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Description: The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
Study NCT02736981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BWL + Autonomous Motivation
Description: The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
Study NCT02736981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BWL + Extrinsic Motivation
Description: The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
Study NCT03189836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTR707
Description: autologous T cell product
Study NCT03189836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: CD20-directed cytolytic antibody
Study NCT03368235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567
Description: oral OD SGRM administered as suspension
Study NCT03368235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: oral capsules of 20 mg prednisolone administered OD for two weeks
Study NCT03932630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
Study NCT03932630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balanced diet
Description: The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
Study NCT01207310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation counseling
Description: two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
Study NCT01207310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 8 weeks' worth of nicotine patches
Study NCT01207310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 8 weeks' worth of nicotine patches
Study NCT01207310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alphanumeric pager
Description: therapeutic messages to be delivered for three months
Study NCT02012270 — intervention group
Intervention type: PROCEDURE
Intervention: PRINCIPLES technique
Description: Principles technique for closure of midline laparotomy incisions~* closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)~* the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other~* the SL/WL ratio should be at least 4/1~* SL/WL = (150cm x number of sutures used) - (the suture remnants)~* the mean stitch length should be less than 4 cm (suture length / number of stitches placed)
Study NCT02012270 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional group
Description: the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
Study NCT01238107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-102
Description: BETA BLOCKER
Study NCT01238107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT-102
Description: BETA BLOCKER
Study NCT04052620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac diethylamine 2.32% gel
Description: Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
Study NCT04052620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine 1.16% gel
Description: Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
Study NCT04052620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
Study NCT03649984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Navi© Program
Description: Trained nurses provide two semi-structured patient education consultations with Symptom Navi© Flyers. Patients will use the Symptom Navi© Flyers individually at home.
Study NCT02690987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of \~130-190 pg/mL.
Study NCT02690987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Desacyl ghrelin
Description: Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. Good Manufacturing Practice (GMP)-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).~The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of \~13-19 ng/mL.
Study NCT02690987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: The placebo visit will involve an intravenous infusion of normal saline.
Study NCT04496518 — intervention group
Intervention type: DEVICE
Intervention: Intrinsic Antitachycardia Pacing (iATP) Therapy
Description: iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).